SC-514

SC-514 is an inhibitor of IKK and CDK2 used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. In practice, this places the compound in experiments that measure inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses in cancer, cell cycle, and immunology models.

By inhibiting IKK and CDK2, SC-514 can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The signaling pathway modulator annotation adds relevance to pathway-reporter and mechanistic-phenotyping studies, together with downstream-response mapping in the same experimental setting. In cancer, cell cycle, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving IKK and CDK2
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Pathway-reporter and mechanistic-phenotyping studies

Overall, SC-514 is appropriate when a defined chemical perturbant is needed to connect IKK and CDK2 with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell cycle, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.